Nervgen Pharma Corp.
NGEN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001751912
No open-market purchases or sales by Nervgen Pharma Corp. insiders were filed in the last 90 days; 62 institutions reported holding it in 13F filings for Q2 2026, worth $24.9M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +17 vs. previous quarter
- 62
- 13F valueReported value at the end of Q2 2026
- $24.9M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding NGEN, Q2 2026
No superinvestor reported holding NGEN at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Nervgen Pharma Corp. insiders from Form 4, newest first.
No open-market purchases or sales by Nervgen Pharma Corp. insiders are on file.
Top 10 13F holders, Q2 2026
The largest institutional positions in Nervgen Pharma Corp. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Empery Asset Management, LP | 4,000,000 | $8.24M | 9.53% | +4,000,000 | New |
| Rock Springs Capital Management LP | 1,208,231 | $2.49M | 0.12% | +1,208,231 | New |
| DAFNA Capital Management LLC | 1,050,000 | $2.16M | 0.41% | +1,050,000 | New |
| Ghisallo Capital Management LLC | 1,000,000 | $2.06M | 0.04% | +1,000,000 | New |
| Armistice Capital, LLC | 678,000 | $1.40M | 0.04% | +678,000 | New |
| LMR Partners LLP | 600,000 | $1.24M | 0.01% | +600,000 | New |
| Marshall Wace, LLP | 435,962 | $898.1K | 0.00% | +235,603+117.6% | Added |
| UBS Group AG | 379,726 | $782.2K | 0.00% | +318,209+517.3% | Added |
| Stonepine Capital Management, LLC | 271,678 | $559.7K | 0.43% | +271,678 | New |
| Jane Street Group, LLC | 270,750 | $557.7K | 0.00% | +270,750 | New |